TransMedics Group Inc (TMDX) stock saw a decline, ending the day at $68.81 which represents a decrease of $-3.74 or -5.16% from the prior close of $72.55. The stock opened at $62.93 and touched a low ...

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals ...

TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as ...

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMe ...

Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

TransMedics Group Inc (TMDX) stock saw a decline, ending the day at $72.55 which represents a decrease of $-6.12 or -7.78% from the prior close of $78.67. The stock opened at $75.81 and touched a low ...

Detailed price information for Transmedics Group Inc (TMDX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Transmedics Group Inc (TMDX-Q) from The Globe and Mail including charting and trades.

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today ...

BOSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating TransMedics Group, Inc. (Nasdaq: TMDX) for potential securities law violations. Investors who have lost money in their ...